Summit Therapeutics Inc.
Summit Therapeutics Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 10, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 16.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 7 concluded trials, 71% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 10, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| April 15, 2028 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Trial Milestone | Phase 3 |
| May 31, 2028 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Trial Milestone | Phase 3 |
| December 31, 2028 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Trial Milestone | Phase 3 |
| October 31, 2030 | A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma | Trial Milestone | Phase 2/Phase 3 |
Track SMMT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SMMT in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.